Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) said the results from a successful phase IIb clinical trial of its drug for chronic obstructive pulmonary disease (COPD) have been published in a peer-reviewed scientific journal.
Respiratory Research carried the data from Verona’s four-week, 400-patient study first released in 2018.
The results showed the company’s drug, ensifentrine, produced a clinically and statistically significant improvements in lung function at all doses.
Also, secondary targets were achieved, including significant progressive improvements in COPD symptoms.
The paper can be accessed here.